here - International Vaccine Institute

국제백신연구소 해피빈
012
rt 2
o
ep
lR
a
nu
An
Vaccines, Children, and a Better World
Preventing Infectious Diseases through Science
Copyright 2013 – International Vaccine Institute. All rights reserved International Vaccine Institute
Seoul National University Research Park, San 4-8 Nakseongdae-dong, Gwanak-gu, Seoul, Korea 151-919
Tel: +82 872 2801 Fax: +82 2 872 2803. Contact: iviinfo@ivi.int
www.ivi.int
te
titu
s
In
ine
c
c
l Va
na
o
i
at
ern
Int
Annual Report 2012
International
Vaccine
Institute
Vaccine discovery, development, and delivery
Capacity-building
Improving Health
Saving Lives
IVI IN BRIEF
Vaccines are one of the most cost-effective tools used in public
health and have contributed to significantly reducing the spread
and burden of infectious diseases. They played a major role in
eradicating smallpox and are being used in initiatives to eliminate
polio and measles. However in 2011, the World Health
Organization (WHO) estimated there were 6.9 million deaths of
children under the age of five. Of these deaths, 58% were due to
infectious diseases and many occurred in Africa and South Asia.
The International Vaccine Institute (IVI) was founded in 1997 on
the belief that the health of children in developing countries can be
dramatically improved by the development, introduction, and use
of new and improved vaccines. Working in collaboration with the
international scientific community, public health organizations,
governments, and industry, IVI is involved in all areas of the
vaccine spectrum - from new vaccine design in the laboratory to
vaccine development and evaluation in the field to facilitating
vaccine introduction in countries where they are most needed.
•Number of IVI staff: 150
•Countries represented by IVI staff: 16
•Number of countries where IVI works: 23
“Lab bench to community” approach
IVI’s research platform spans from “bench to community” from
designing a new vaccine in the laboratory to developing and testing
the vaccine to making sure that the vaccine will be introduced and
used in countries. IVI is able to do this through its in-house
programs in laboratory and translational research. This broad range
allows IVI to develop a new vaccine or improve an existing one;
develop assays and conduct clinical trials in humans; transfer the
production technology to vaccine manufacturers; and conduct
studies to demonstrate the need for the vaccine and make the case
for its use to global-and national-level decision makers and donor
agencies.
IVI’s Approach
IVI’s Disease Priorities
IVI IN BRIEF
03
LETTER FROM
THE DIRECTOR GENERAL
We went live with a new electronic financial management system
in November, giving IVI a level of transparency and reliability that
is comparable to many strong international organizations of its
kind. We worked on a new transparent compensation & benefits
system that is critical to attracting and retaining talent at IVI.
With the support of our Board, Scientific Advisory Group, and
major donors, we redesigned our vision, mission, and strategy,
which will bring more focus and clarity in how we will make an
impact in the world through vaccines. As a part of this exercise, we
changed the organizational structure and look forward to the
introduction of a new structure as soon as critical positions are
filled. This work was made possible thanks to support from the Bill
& Melinda Gates Foundation.
Christian Loucq, MD
Director General
It is my pleasure to present IVI’s Annual Report for 2012. There
are very few places around the world that are entirely dedicated to
vaccines and vaccination for developing countries. There are also
very few places with a vaccine portfolio that comprises of a vaccine
approved by the World Health Organization (WHO), a vaccine in
the clinical development phase, and another vaccine that will cross
from the lab to the field for clinical trials.
IVI is a place of passion for a concept that has allowed humanity
since the time of Louis Pasteur to control and eradicate diseases.
IVI is a place of dedication to the concept that vaccines are the
most cost-effective tool against infectious diseases. IVI is a place
where scientists from all over the world are working hard together
against diseases that affect the poorest of the poor. Earlier in my
career when I began working on vaccines at the Institut Pasteur
Production, I was in Zaire (today’s Democratic Republic of the
Congo). A deadly cholera epidemic plagued the southern province
of Shaba. Three decades later coming back to the same field, I am
saddened to see this disease is in many African countries and has
expanded to Haiti and even Cuba.
Cholera is unfortunately one of many infectious diseases that are a
part of the vicious circle of poverty. It is why a place like IVI has
such an important role to play and is worth fighting for. The year
2012 was a difficult year for IVI. It was a year that saw financial
challenges but also opportunities for IVI to redefine and enhance
itself. After 15 years of existence, it is the right time for IVI to
consider its next phase as an organization.
In 2012, under a new management team, a lot of time and effort
was spent on strengthening our governance. A new governance
structure was approved by the IVI Board of Trustees in December.
A smaller Board that meets more frequently is already bringing
much stronger organizational oversight. Prof. Adel Mahmoud was
appointed as Board Chair, replacing Prof. Ragnar Norrby who
completed his term as Board Chair. I thank Prof. Norrby for his
years of service, and I welcome Prof. Mahmoud who will be
instrumental in helping usher in the changes at IVI.
We are very pleased to establish more meaningful collaborations in
the Republic of Korea, IVI’s host country. We are partnering with
SK Chemicals for the co-development of a new typhoid conjugate
vaccine and with Korea National Institute for Health for joint
research projects. In December, Hyundai-Kia Motors became a
donor and is supporting the introduction of the oral cholera
vaccine in Malawi.
The year 2012 also saw the departure of Dr. Cecil Czerkinsky,
Deputy Director General of Laboratory Sciences, after seven years
of service. We are grateful for his immense contribution to IVI.
Dr. Alejandro Cravioto and Dr. Georges Thiry joined as Chief
Scientific Officer and Deputy Director General Portfolio
Management, respectively. These new positions will help ensure
our focus and alignment on the science and programs. Despite a
year of transition, our scientists have kept projects moving forward
in approximately 20 countries in Africa, Asia, and Latin America.
I would like to thank the Government of the Republic of Korea,
the Bill & Melinda Gates Foundation, and the Swedish
International Development Cooperation Agency (Sida) for their
continued trust and confidence in IVI. I also thank our Korean
partners LG Electronics, Hyundai-Kia Motors and the Korea
Support Committee for IVI (KSC) for their support, in addition to
numerous other donors and supporters.
In 2013, we have embarked on an important project to have
countries that are party to our Establishment Agreement support
IVI in its strategy and financing. With a more diversified funding
base, IVI will be well-poised to bring new vaccines to poor
populations in this world and to help bridge the gap between
vaccines and vaccination. We will make the necessary impact to
achieve our vision of developing countries free of suffering from
infectious disease.
Sincerely,
A YEAR OF CHANGE
AND NEW BEGINNINGS
On October 9, 2012, IVI commemorated its 15th year as an
independent nonprofit international organization based in Seoul,
Republic of Korea. IVI was originally founded as an initiative by
the United Nations Development Program (UNDP) on the belief
that the health of children in developing countries can be
dramatically improved by the use of vaccines. Since its
establishment 15 years ago, IVI has made many contributions to
global health and the vaccine sciences with generous support from
its host country, the Republic of Korea, and other major
supporters such as the Bill & Melinda Gates Foundation and the
Swedish International Development Cooperation Agency (Sida).
As IVI looks to the next 15 years, it recognized some fundamental
changes needed to be made to the organization to maximize its
impact in developing countries. It embarked on a series of activities
to strengthen and enhance its organizational capacity. The new
initiatives will help position IVI so it can better deliver on the
mandate that it was charged with at its inception: to improve the
health of children in developing countries through the
development, introduction, and use of new and improved vaccines.
New Vision, Mission, Values, and Strategy
The year 2012 saw IVI re-assessing its direction, a year-long
undertaking that involved consultations with staff, the Board of
Trustees, the Scientific Advisory Group, and major stakeholders.
In the process, IVI’s vision and mission were redefined and
clarified. The new vision and mission statements clearly
communicate IVI’s aspiration and purpose.
A YEAR OF CHANGE AND NEW BEGINNINGS
05
A set of values was developed. The values are representative of what
IVI staff and stakeholders believe the organization should embody.
The values will help drive the organizational culture, priorities, and
provide a compass point on how actions and decisions at the
organization should be made.
Our Values
Excellence
We strive to be leaders in scientific excellence
and innovation.
Dedication
We are committed to saving lives and improving
the health of the world’s poorest people through
vaccines.
Integrity
We value transparency and adhere to the
highest ethical standards in our work.
Respect
We are team players who embrace diversity
and treat others with dignity and equality.
Accountability
We are responsible for our actions to each
other, our stakeholders, and the people we serve.
A five-year strategic plan (2013-’17) was developed as a road map
on how IVI will achieve its mission. The plan was approved by the
Board in December 2012. The new strategy is based on four major
goals, which aim to: achieve public health impact, fill the vaccine
development pipeline, contribute to innovative vaccine discoveries
in basic research, and build developing country capacity in
vaccinology. For each goal, there are specific indicators to measure
progress.
Our Goals:
1. Accelerate the development and introduction of safe and
effective vaccines;
2. Discover and pursue proof of concept for new vaccine
candidates;
3. Advance science driving new achievements in vaccinology;
and
4. Contribute to building vaccine technology and systems
capacity.
IVI’s Strategic Plan (2013-’17)
VISION
Developing countries free of suffering from infectious disease
MISSION
Discover, develop, and deliver safe, effective, and affordable vaccines for the world’s developing nations
GOAL-LEVEL INDICATORS
GOALS
3. Advance science
driving new
achievements
in vaccinology
4. Contribute to
building vaccine
technology and
systems capacity
CHOLERA
TYPHOID
DENGUE /
OTHER EDD
2. Discover and
pursue proof of
concept for new
vaccine
candidates
ShancholTM support
studies completed
Vi-PS impact
demonstrated and
scale up introduction
Revised Dengue
program strategy
defined
Next-generation
cholera vaccine in
development
Scientific
advancements
in vaccinology &
immunology
published
DPRK surveillance in
place and JE vaccine
introduced nationally
Sufficient vaccine
supply to enable
stockpile &
multiple country
introductions
Vi-conjugate
development &
introduction progress
Dengue vaccine
development
partnerships
established
Next-generation
typhoid vaccine(s) in
development
Conduct basic
research to develop
vaccine enhancing
technologies
Ensure technology
transfer of portfolio
vaccines to multiple
suppliers
Hepatitis E
vaccine program
in place
Shigella vaccine
program go/no go
decision made
Tech support
relationships with field
laboratories
maintained &
expanded
EDD-focused
surveillance sites
established and
generating data
Conduct feasibility
studies to determine
disease go/no go
decisions
Conduct basic
research to better
understand
immunological
responses to
vaccines
Korean research organization partnerships
established. Candidates identified and
research programs resourced
Respected post-doc
program supporting
Korean scientists in
place
1. Accelerate development and introduction
of safe and effective vaccines
Published evidence to Published evidence to
support introduction support introduction
decision-making
decision-making
Korean vaccine manufacturers leveraged to improve supply security
and pricing. Korean technology companies leveraged to improve
delivery system
Vi-PS: Vi-polysaccharide vaccine
DPRK: Democratic People’s Republic of Korea
06 IVI 2012 ANNUAL REPORT
EDD: Enteric and diarrheal diseases
JE: Japanese encephalitis
Improved and
expanded
vaccinology
course available
IVI’s strategy continues to prioritize cholera, typhoid, and dengue
as the organization’s three main disease pillars but it acknowledges
new diseases of strategic research interest at IVI (e.g., hepatitis E,
norovirus). The plan also prioritizes collaborations with domestic
vaccine manufacturers and research organizations in South Korea
in order to capitalize on the country’s expanding vaccine industry,
and resources and talent in biomedical research.
New Governance
IVI revisited its governance in response to recommendations by
stakeholders that it needed to be strengthened. An independent
assessment of IVI’s governance was made followed by an intense
six months of work by a Governance & Nominating Committee to
restructure the governance. In December 2012, a new governance
structure was approved by the Board of Trustees. The new
governance structure consists of a smaller Board that will meet
more frequently. This has been implemented and signs of robust
oversight and increased commitment by Board members are
already being seen.
The new governance structure will also comprise of a new body,
the Council, where countries that are party to IVI’s Establishment
Agreement and entities that are financially supporting the
organization will sit. The Council will allow IVI to diversify its
funding base by providing access to new avenues of unrestricted
funds from IVI’s signatory countries, as well as serve as a platform
for more country engagement in IVI’s programs and strategy.
At the end of 2012, Prof. Adel Mahmoud was appointed as the
new Chair of the IVI Board, succeeding Prof. Ragnar Norrby who
completed his term as Board Chair.
New Organization
To support the new strategy and to increase the organization’s
capacity to deliver on its mission, IVI also worked on developing a
new organizational structure, which was reviewed and approved by
the Board in June 2012. The new structure comprises of a matrix
system and has a strong focus on portfolio and project
management with the introduction of a Portfolio Management
Unit and Portfolio Management Committee. Two new positions
were also introduced: a Deputy Director General of Portfolio
Management and a Chief Scientific Officer (CSO). These elements
will help make IVI a more focused organization that is better
aligned with its programs and a better manager of the programs in
its portfolio.
New Systems
Several measures were made in 2012 to improve the effectiveness
and efficiency of IVI’s operations. A new Enterprise Resource
Planning (ERP) system was implemented that will increase the
transparency of all financial transactions at IVI. An internal control
system is in the process of being developed. These measures will
help increase IVI’s donor funding stewardship, the transparency of
its operations, and the reliability of its reporting. In Human
Resources, a new staff compensation & benefits structure was
developed and implemented for all IVI staff. Job grade definitions
are in the process of being developed and analyzed. This will be
important in order to limit high turnover and to put IVI in a
competitive position to recruit high-quality staff.
New Partners
IVI brought onboard several important new partners, particularly
Korean partners, in 2012. A partnership was formed with SK
IVI - New Organizational Structure
A YEAR OF CHANGE AND NEW BEGINNINGS
07
Chemicals, a member company of the SK Group, the third largest
conglomerate in South Korea. SK Chemicals and IVI entered into
an agreement for technology transfer and manufacture of a new
typhoid Vi-conjugate vaccine developed at IVI. This agreement
marks IVI’s second industrial collaboration in Korea (IVI also has
one with Eubiologics, a biotechnology firm, for the manufacturing
of the oral cholera vaccine that IVI reformulated). It also indicates
a growing interest and investment in vaccines by the Korean
industry.
In parallel, IVI formed a partnership with Biofarma, a state-owned
vaccine manufacturer in Indonesia for the manufacturing of its Viconjugate vaccine.
IVI also entered into an agreement with the Korea National
Institute of Health (KNIH), one of Korea’s primary research
agencies. KNIH and IVI will work together on joint vaccine
research projects and initiatives to share scientific information.
Work still continued
Throughout the transitional changes, IVI continued to make
progress in its programs from basic research conducted in
laboratory facilities at its headquarters in Seoul; to translational
research at field sites in 23 countries in Asia, Africa, and Latin
America; to training and capacity-building.
The IVI team heading to a hospital at a field site in Kibera, Kenya for the
Typhoid Fever Surveillance in Africa Program (TSAP).
08 IVI 2012 ANNUAL REPORT
We are and will remain committed toward realizing our vision
of a world where the poorest people are free of suffering from
infectious disease due to the powerful impact of vaccines and
vaccination.
2012 MILESTONES
IVI’s New Board Chair - Prof. Adel Mahmoud
Prof. Mahmoud is a Professor in Molecular Biology and
Public Policy at Princeton University and was President of
Merck Vaccines. Prof. Mahmoud brings to IVI a wealth of
experience in the vaccine sciences from academia and
industry.
Launch of a new mission, vision, values, five-year strategic plan (2013’17), organizational structure, systems, and governance - important
changes that will help the organization focus on its mandate and
increase its ability to deliver on its mission and vision.
New appointments on IVI’s Board and management to help the
organization deliver. Prof. Adel Mahmoud became Chair of the
Board at the end of 2012, succeeding Prof. Ragnar Norrby who
served as the Board Chair since 2006.
Dr. Alejandro Cravioto was appointed in October as the Chief
Scientific Officer (CSO), a newly created position to oversee IVI’s
scientific direction; and Dr. Georges Thiry joined at the year’s end
as Deputy Director General, Portfolio Management to oversee
IVI’s newly established Portfolio Management Unit. Dr. Cravioto
was the former Executive Director of icddr,b, and Dr. Thiry was
the Director of Portfolio and Project Management and Director of
Advancing New Rotavirus Vaccines (ARVAC) at PATH.
Strengthening partnerships through the new organizational changes. In
October 2012, IVI organized a Donors’ Day that was attended by
representatives of current stakeholders such as the Bill & Melinda
Gates Foundation (BMGF), the Swedish International Development
Cooperation Agency (Sida), the Korean Government (Ministry of
Education, Science, and Technology), and the GAVI Alliance. It
was an opportunity for IVI to present its new strategic plan and to
get input from its donors and partners. More importantly, it
helped strengthen relationships with key partners, culminating in
renewed support from Sida and BMGF.
IVI Director General, Dr. Christian Loucq, and SK Chemicals CEO, Mr. Kim
Chang-geun, at the IVI - SK Chemicals MOU signing ceremony in October
2012.
Formation of key partnerships in South Korea to advance vaccine
research in Korea and beyond. IVI established an agreement with SK
Chemicals for the technology transfer, clinical development, and
manufacture of a new typhoid conjugate vaccine. IVI will transfer
the technology to SK Chemicals who has agreed to supply the
vaccine for the public sector, particularly for developing country
markets. IVI also forged partnerships with two Korean research
organizations, Korea National Institute of Health (KNIH) and
Transgovernmental Enterprise for Pandemic Influenza in Korea
(TEPIK), to collaborate on vaccine R&D and information-sharing.
IVI will be working with KNIH on research projects on norovirus
and RSV.
Change in public opinion on cholera vaccination, creating momentum
for the use of the oral cholera vaccine developed by IVI to control
outbreaks. Developed with the public sector in mind, the two-dose
killed whole-cell oral vaccine is low-cost, safe, and has a protective
efficacy of 66 percent for three years in persons one year old and
up. The vaccine was WHO-prequalified in 2011. Despite the
availability of the vaccine, doubts prevailed about the feasibility of
vaccination to control cholera in outbreaks. However results from
mass vaccination demonstration projects with the oral cholera
vaccine in Haiti and Guinea have shown that vaccination can work
in the midst of an outbreak. There has been heightened urgency to
step up cholera prevention and control efforts due to the alarming
spread of cholera from Haiti to the Dominican Republic and even
Cuba, which hadn’t seen cholera cases since the 1800s. Interest by
2012 MILESTONES
09
WHO, PAHO, and the U.S. Centers for Disease Control (CDC)
has emerged in the use of the oral cholera vaccine as a short-term
measure to curb illness in outbreaks and as part of a comprehensive
disease control program - along with increasing access to clean
water and sewage treatment. The WHO has called for the
establishment of a global cholera vaccine stockpile to respond to
outbreaks like Haiti’s.
Launch of a program in the Democratic People’s Republic of Korea
(DPRK; North Korea), In late 2012, IVI received funding from
South Korea’s Ministry of Unification (MOU) for its North Korea
Program, the only organization in South Korea to receive support
from MOU for North Korean aid in 2012. The program aims to
reduce illness and death from diarrheal disease and acute
encephalitis syndrome in North Korean children by building
country capacity in vaccine introduction. Capacity-building and
training activities will be conducted for North Korean scientists
and health professionals in areas such as disease surveillance and
laboratory diagnostics. A vaccinology workshop was conducted for
North Korean scientists from the Academy of Medical Sciences in
Hanoi, Vietnam from December 2-9 in collaboration with
Vietnam’s National Institute of Hygiene and Epidemiology
(NIHE).
North Korean scientists take part in a vaccinology workshop organized by IVI in
Hanoi, Vietnam in December 2012.
10 IVI 2012 ANNUAL REPORT
2012 IN BRIEF
January:
Two U.S. patents granted for novel Shigella common protein
antigens discovered by IVI.
March:
IVI’s estimation of the global burden of cholera published in The
Bulletin of the WHO; 1 and official publication of a country
investment case study for oral cholera vaccines for Bangladesh
(publication can be accessed at: http://www.ivi.org/web/www/04_03).
May:
Her Majesty Queen Silvia of Sweden visits IVI as part of her
official visit to the Republic of Korea.
June:
The Blue & Green Ribbon Charity Gala held in collaboration with
the Korean nonprofit organization Green Tree Foundation in
order to raise funds to support the health and wellbeing of children
in North Korea.
MOU signed with the Transgovernmental Enterprise for Pandemic
Influenza in Korea (TEPIK) to collaborate on vaccine research and
information-sharing.
Her Majesty Queen Silvia of Sweden greeted by IVI Director General, Dr. Christian
Loucq, and with flowers in the lobby of IVI’s headquarters.
July:
MOU signed with the Sabin Vaccine Institute to collaborate on
joint advocacy and information-sharing activities.
MOU signed with the Korea National Institute of Health to
collaborate on vaccine R&D projects.
October:
IVI celebrates its 15th year anniversary.
MOU signed with SK Chemicals for technology transfer and
production of a typhoid conjugate vaccine developed by IVI.
Donors’ Day at IVI in which donors like the Bill & Melinda Gates
Foundation, the Swedish International Development Cooperation
Agency (Sida), and the Korean Government were invited to
provide feedback on IVI’s new strategy
IVI staff celebrates the organization’s 15th anniversary at the IVI headquarters.
November:
IVI’s Institutional Review Board (IRB) re-recognized by the
Forum for Ethical Review Committees in the Asian and Western
Pacific Region (FERCAP).
December:
Funding granted from Hyundai-Kia Motors to IVI for a cholera
vaccination project in Malawi.
Funding granted from the Bill & Melinda Gates Foundation to
IVI to support implementation of organizational changes taking
place.
1
Ali M, Lopez AL, You YA et al. The global burden of cholera. Bull World
Health Organ 2012/Mar; 90(3): 209-218A.
2012 IN BRIEF
11
GEOGRAPHIC RANGE OF
IVI’S WORK IN 2012
12 IVI 2012 ANNUAL REPORT
RESEARCH HIGHLIGHTS
Cholera
IVI’s Cholera Vaccine Program aims to make safe, effective, and
affordable oral cholera vaccines available and accessible to
developing countries for the control of endemic and epidemic
cholera. IVI has been working on the development of two
vaccines-a killed whole-cell oral cholera vaccine and a live
attenuated oral cholera vaccine. Among the two, IVI has made the
most headway on the killed whole-cell oral cholera vaccine. The
vaccine, which was reformulated by IVI, was tech-transferred to
Shantha Biotechnics in India where it was licensed as ShancholTM‚
in 2009. It received WHO prequalification in 2011. Developed
with the public sector in mind, the two-dose vaccine is available on
the market at a relatively low cost and can be given without a
buffer, simplifying its administration in resource-limited settings.
The vaccine has been demonstrated to provide about 66 percent
protection for up to three years in people one year old and up. To
ensure an adequate supply of oral cholera vaccines for the global
market, IVI is working with a second manufacturer, Eubiologics in
South Korea, for the technology transfer and production of the
vaccine.
In 2012, the oral cholera vaccine received a huge boost due to a
change in opinion by the global health community about cholera
vaccination. Previously, there were doubts and skepticism about
the feasibility of vaccination to control cholera, especially in
outbreaks. However results from mass cholera vaccination
demonstration projects in Haiti and Guinea conducted by Partners
in Health and Medecins Sans Frontieres (MSF), respectively, have
shown that vaccination can work in the midst of an outbreak.
With the alarming spread of cholera from Haiti to the Dominican
Republic and Cuba, and epidemics in Central and West Africa,
there has been heightened urgency to step up prevention and
control efforts. The World Health Assembly (the WHO's
governing body) has called for more effective cholera control,
including the use of cholera vaccines, and the WHO and PAHO
have reconsidered their positions on cholera vaccination. Interest
The IVI team (You Young-ae, left; Kim Yang-hee, fifth from left; and Dr. Binod
Sah, center) with local collaborators in Orissa, India.
has emerged in the use of the oral cholera vaccine as a short-term
measure to curb illness in outbreaks and as part of a comprehensive
disease control program-along with increasing access to clean water
and sewage treatment. The WHO has called for the establishment
of a global cholera vaccine stockpile to respond to outbreaks like
Haiti’s.
Against this backdrop, IVI continued to work on promoting the
availability and access of the oral cholera vaccine. In 2011, IVI in
collaboration with the local government conducted a vaccination
demonstration project in Orissa state (official name: Odisha), India
in order to assess the feasibility of mass vaccination with the oral
cholera vaccine using the public health system, the first study of its
kind in India. The findings showed that mass vaccination
targeting a community of about 36,000 with the two-dose vaccine
was feasible and cost-effective. Publication of the results is
forthcoming. Based on the promising results, a mass vaccination
targeting the high-risk tribal communities in Orissa is being
planned by the government with support from IVI.
IVI, in collaboration with the Ethiopian government and local
partners such as the Armauer Hansen Research Institute (AHRI),
continued to work on preparations for a pilot mass vaccination
campaign with the oral cholera vaccine in Ethiopia supported by
LG Electronics. The vaccination is anticipated to occur in 2013.
At the end of 2012, IVI received support from Hyundai-Kia
Motors to introduce the oral cholera vaccine in Malawi. This
project will start in 2013.
IVI continued to provide technical assistance to icddr,b as part of
ongoing efforts to introduce the oral cholera vaccine in Dhaka,
Bangladesh. Approximately 141,000 people were vaccinated
through a demonstration project in 2011 to evaluate the feasibility
and effective of cholera vaccination and other control interventions.
As part of a global investment case for oral cholera vaccines, IVI
developed and published a Bangladesh case study in 2012.
Intended for policymakers, vaccine manufacturers, and donors, the
report provides an estimate of the disease and economic burden,
financing needs, likely challenges, and cost, impact and costeffectiveness estimates for several cholera vaccination strategies.
The report can be accessed at: http://www.ivi.org/web/www/04_03.
Clinical studies continued for the killed whole-cell oral cholera
vaccine (OCV). Five years of surveillance was completed for the
extended Phase III trial of Shanchol in Kolkata, India to assess the
protective efficacy of the vaccine after five years. Publication of the
results is expected in 2013. Additional studies to optimize the use
of Shanchol such as a single-dose efficacy trial and assessment of
immunogenicity after varying intervals between doses are ongoing.
Donors: Bill & Melinda Gates Foundation, Swedish International
Development Cooperation International Agency (Sida), LG
Electronics, Hyundai-Kia Motors, and the Government of the
Republic of Korea
RESEARCH HIGHLIGHTS
13
Typhoid
The goal of IVI’s Typhoid Vaccine Program is to reduce the
burden of typhoid fever in the developing world by making
vaccines available and accessible to populations at risk in Asia and
Africa. The program has two objectives: 1) to accelerate the
development and delivery of safe, effective, and low-cost Vi-based
vaccines in endemic countries in Asia; and 2) to generate evidence
on the burden of typhoid fever and other invasive Salmonella
infections in Africa, for which scientifically sound data are limited.
IVI’s Vi-based Vaccines for Asia (VIVA) Initiative aims to accelerate
the introduction and use of typhoid vaccines in endemic countries
in Asia through demonstration projects, and policy and advocacy
activities; and the development of a new typhoid Vi-conjugate
vaccine. More than 300,000 school children were vaccinated with
the Vi-polysaccharide vaccine in Karachi, Pakistan and
Kathmandu, Nepal through school-based vaccination campaigns
that were conducted in collaboration with the local government.
Case-control studies are ongoing in Kathmandu to assess the
impact of vaccination. A typhoid consultation meeting was
convened by IVI with local media, policymakers, and stakeholders
in Kathmandu in July 2012 to share findings from the vaccination
campaign and to discuss strategies on typhoid control. The
meeting culminated in an endorsement by the Health Secretary on
the use of typhoid vaccines and a commitment by the local
government to expand the vaccination campaign to high-risk areas
and groups in Kathmandu.
Nepali school children who were vaccinated against typhoid through a campaign
coordinated by IVI displaying their vaccination cards.
age-structured, compartmental model of typhoid transmission was
developed for urban slum populations in two countries-India and
Pakistan-to estimate the population-level impact of vaccination,
which was simulated over a 20-year period after a one-time Vipolysaccharide vaccination campaign for children ages 2 to 14.9
years. This model has the potential to help better understand how
the disease is transmitted in populations and predict the effect of
mass vaccination in controlling the disease. Additionally, the
model outputs allow better estimation of cost-effectiveness.
The Typhoid Fever Surveillance in Africa Program (TSAP) aims to
generate data on the burden of typhoid fever and other invasive
Salmonella infections through standardized surveillance and disease
burden studies among a network of 10 African countries (Guinea
Bissau, Senegal, Burkina Faso, Madagascar, South Africa,
Tanzania, Ghana, Kenya, Ethiopia, and North Sudan). In 2012,
all 10 sites were active and reporting data. Results so far show that
Salmonella Typhi and/or other Salmonella species are present in
nine countries, primarily affecting children. IVI continued to
provide technical support to these sites while expanding the
typhoid surveillance platform to support other disease burden
studies for diseases such as cholera and dengue. Two sub-studies
were added to TSAP that include a study to identify factors
affecting health care facility use by patients with fever in order to
discern any patterns of variability in factors across all TSAP sites,
and a study to identify carriers of S. Typhi, S. Paratyphi and nontyphoidal Salmonella (NTS)-the bacterial agents of typhoid,
paratyphoid and invasive salmonellosis, respectively, in the general
population and among household members of confirmed cases in
Guinea Bissau and Senegal. Finally, sites were identified for Phase
II/III clinical trials to evaluate new conjugate vaccines against
typhoid and invasive salmonelloses that are currently under
development.
Donors: Bill & Melinda Gates Foundation, Swedish International
Development Cooperation International Agency (Sida), and the
Government of the Republic of Korea.
Work continued on clinical development of the Vi-conjugate
vaccine that was developed by IVI based on conjugation
technology from the U.S. National Institutes of Health. Following
the technology transfer to Shantha Biotechnics, clinical trial lots
have been produced by Shantha and preparations are being made
to begin the first clinical trial in India. In addition, IVI formed
partnerships with SK Chemicals (South Korea) and BioFarma
(Indonesia) for technology transfer and production of the Viconjugate vaccine. These additional manufacturers will help ensure
an adequate and affordable supply of Vi-conjugate vaccines for the
global market.
Work on a global investment case for typhoid vaccines and disease
transmission model are ongoing, which should help make the case
to donors and policymakers on the need for typhoid vaccines. An
14 IVI 2012 ANNUAL REPORT
Mothers and their infants queuing for vaccination at the Bandim Health Clinic in
Bissau, Guinea-Bissau, one of the TSAP enrolment facilities.
Dengue
IVI is the lead coordinating agency of the Dengue Vaccine
Initiative (DVI; http://www.denguevaccines.org), a consortium
consisting of IVI, the Sabin Vaccine Institute, WHO’s Initiative
for Vaccine Research (IVR), and the International Vaccine Access
Center (IVAC) at Johns Hopkins University. DVI’s mission is to
encourage the development and use of vaccines to prevent dengue.
The consortium works to maintain a pipeline of dengue vaccine
candidates and to create an enabling environment for dengue
vaccine introduction in four countries that are considered to be
early adopters of dengue vaccines: Brazil, Colombia, Thailand, and
Vietnam. In 2012, IVI, in collaboration with local research
partners, continued to conduct various studies such as disease
burden, cost-of-illness, and health care utilization studies, as well as
seroprevalence and willingness-to-pay surveys at the field sites in
the four countries. DVI’s Asia-Pacific and Americas Dengue
Prevention Boards had their annual meetings, which led to the
drafting and subsequent publication of “Points for Consideration
for First-to-Introduce Countries of Dengue Vaccines.” In addition,
IVAC published “Costing Dengue Cases and Outbreaks: A Guide
to Current Practices and Procedures,” which aims to ensure robust
assessment of the economic burden of dengue infections.
Late 2012 also saw the anticipated publication of the Phase IIb
trial results from Sanofi Pasteur for its live attenuated tetravalent
dengue vaccine, the first study to evaluate the efficacy of a dengue
vaccine candidate against clinical disease in a population naturally
exposed to dengue. The results were not as encouraging as had
been hoped, with the most virulent strain resisting the vaccine.
However the vaccine showed promising safety results and some
protection against the other three dengue strains. The WHO
Advisory Committee on Dengue and other Flavivirus Vaccines met
to review the implications of the trial results. The WHO
concluded that the data from the Phase IIb study did not prove or
disprove vaccine efficacy against disease caused by any of the four
dengue virus serotypes and that further studies in larger
populations and different epidemiological setting were needed. In
the dengue vaccine landscape, it reinforced the need for the
development of other dengue vaccines, in addition to the Sanofi
Pasteur candidate.
Donors: Bill & Melinda Gates Foundation, Inviragen, Sanofi Pasteur.
The local study team and field coordinator Diana Carolina Velez (second from right)
visiting households for blood collection for the serological survey in Santa Cruz
communa in Medellin, Colombia.
RESEARCH HIGHLIGHTS
15
Discovery and Preclinical Studies
IVI’s basic research focuses on the exploratory and preclinical
stages of vaccine development. It involves studying the immune
response to vaccines and the genetic makeup of infectious
pathogens, with the aim of discovering new vaccine targets, agents
and vectors, as well as developing clinical diagnostic assays to assess
vaccine performance. Potentially promising vaccine candidates are
evaluated for proof-of-concept and efficacy in animal models.
In 2012, IVI was granted two U.S. patents for novel Shigella
protein antigens, which will contribute to efforts in the
development of a Shigella vaccine. The patents, which will expire
in 2029, were filed following IVI’s discovery of common protein
antigens in several Shigella species that could be used as the basis
for a universal vaccine against bacillary dysentery and diagnostic
assays. In addition, the lipopolysaccharide (LPS) length of a
Shigella strain was genetically modified in efforts to potentially
develop a live attenuated vaccine that could protect against the
main Shigella serotypes by enhancing the response to other
membrane proteins. This work is being done in a mouse
pulmonary model.
Enrolment of young children and measurement of
immunogenicity against oral polio virus and rotavirus vaccines
continued in Kolkata, India for the PROVIDE study, a study
supported by the Bill & Melinda Gates Foundation that explores
the effect of under-nutrition as a possible cause of decreased
responsiveness to live oral vaccines, a phenomenon commonly seen
in children from poor countries. IVI is part of an international
consortium that includes the University of Virginia, India’s
National Institute of Cholera and Enteric Diseases (NICED), the
University of Vermont, Stanford University, Washington
University in St. Louis, and Bangladesh’s icddr,b.
Other research highlights included the clarification of the
participation of mucosal dendritic cells in the induction of
protective immunity by vaccines delivered through sublingual or
trans-cutaneous routes, and the development of a novel strategy for
sublingual vaccination with a live attenuated vaccine to control
influenza outbreaks, including pandemics.
IVI scientist Dr. Huan Huu Nguyen conducts vaccine discovery research on
influenza.
16 IVI 2012 ANNUAL REPORT
Process & Formulation Development and Clinical
Development
IVI is also involved in the downstream stages of vaccine
development such as process and formulation development,
clinical development, regulatory review and approval,
manufacturing, and quality control. Cost-effective processes for
large-scale vaccine production are developed and optimized at IVI,
and transferred to qualified vaccine manufacturers in developing
countries. IVI works with manufacturers and regulatory agencies
by providing training and support. Involvement at these stages
will help ensure a sustainable supply of affordable and effective
vaccines for developing countries.
In addition, IVI scientists develop and standardize qualified assays
for measuring human immune responses to vaccines, which are
useful during the clinical development phase. IVI trains researchers
from developing countries on the use of these assays for field
research.
Head of Process Development, Mr. Rodney Carbis, gave a tour of the lab facilities to
the Korean Minister of Health & Welfare, Dr. Rim Che-min in July 2012.
Vaccine Portfolio in 2012
Vaccine
Killed whole-cell oral cholera vaccine
IVI’s Role
Status
IVI, in collaboration with partners in
Sweden, Vietnam, and India enhanced
an existing oral cholera vaccine to meet
international standards set by WHO
enabling global access of the vaccine.
Technology transferred to Shantha
Biotechnics (India). Licensed in India as
Shanchol TM ‚ in 2009 (also licensed in
Vietnam as mORC-VAX). Received WHO
prequalification in 2011. Currently
deployed in endemic and epidemic areas
around the world. Clinical studies to
optimize the vaccine (e.g., single-dose
trial) are under development.
Technology transferred to second
manufacturer Eubiologics (Korea). Clinical
trials to follow.
Vi-polysaccharide typhoid vaccine
IVI improved the production technology
of Vi polysaccharide, resulting in higheryield Vi.
Technology transferred to Shantha in 2009
as part of transfer of Vi-DT conjugate
vaccine technology (see below).
Vi-diphtheria toxoid (Vi-DT) conjugate
typhoid vaccine
IVI developed the new vaccine using
conjugation technology from the U.S.
National Institutes of Health.
Technology transferred to Shantha in 2009
and pilot lots were produced. Clinical trials
to follow. Agreements formed in 2012 with
SK Chemicals (Korea) and BioFarma
(Indonesia) for technology transfer and
production.
Bivalent enteric fever conjugate vaccine
(protects against typhoid and
paratyphoid)
IVI developed the typhoid and
paratyphoid conjugates for the vaccine;
formulation work is ongoing.
Under preclinical development.
Donors: Bill & Melinda Gates Foundation, Swedish International
Development Cooperation Agency (Sida), Korean Ministry of
Education, Science and Technology (MEST), National Research
Foundation of Korea, Korea Research Council of Fundamental Science
and Technology, Korea Health Industry Development Institute, Korea
Exchange Bank, Korea Racing Authority, PATH Vaccine Solutions,
Merck & Co., and World Health Organization (WHO).
RESEARCH HIGHLIGHTS
17
Other Programs
Publications
Several studies neared completion in 2012 such as a retrospective
disease burden study of pneumonia and influenza hospitalizations
in Vietnam that was conducted in collaboration with Vietnam’s
National Institute for Hygiene and Epidemiology (NIHE); and a
retrospective study to detect and identify strains of meningococcal
meningitis in infants and young children in the Asia-Pacific region.
The results suggest there is a previously undetected, yet substantial
burden of meningococcal meningitis in this age group in the
region.
In 2012, there were a total of 79 publications in peer-reviewed
scientific journals by IVI scientists that included The Lancet,
Vaccine, PLoS One, and The American Journal of Tropical Medicine
& Hygiene. For a complete list of publications, please visit the IVI
website: http://www.ivi.org. Highlights include a publication on
the herd effect of the oral cholera vaccine in Zanzibar in The
Lancet Infectious Diseases,2 and a publication on the estimation of
the global burden of cholera using population-based incidence data
and reports in The Bulletin of WHO.3 IVI estimates that globally
there are about 3 million cases and 94,000 deaths due to cholera
per year annually.
Two new projects were launched that include support from the
Yanghyun Foundation for the “Landscape analysis of influenza:
pilot study in Vietnam and Indonesia,” which involve developing
an electronic platform for the collection and analysis of influenza
data from Vietnam and Indonesia; and the “Development and
utilization of educational programs/tools on tuberculosis to high
school students” that will be conducted in Seoul and Incheon City.
Funding for this project was received from the Community Chest
of Korea through the Korea Support Committee (KSC) for IVI.
18 IVI 2012 ANNUAL REPORT
2 Khatib AM, Ali M, von Seidlein L et al. Effectiveness of an oral cholera
vaccine in Zanzibar: findings from a mass vaccination campaign and
observational cohort study. Lancet Infect Dis 2012; 12(11): 837-44.
3 Ali M, Lopez AL, You YA et al. The global burden of cholera. Bull World
Health Organ 2012/Mar; 90(3): 209-218A.
HIGHLIGHTS IN TRAINING
AND CAPACITY-BUILDING
Vaccinology Course
SIVAC Initiative
The 12th Annual International Vaccinology Course in the AsiaPacific Region was held on May 14-19, 2012 at IVI headquarters
in Seoul. Sponsored by the Swedish International Development
Cooperation Agency (Sida), Korea Exchange Bank (KEB)
Foundation, GlaxoSmithKline (GSK), Pfizer, and the Bill &
Melinda Gates Foundation, the week-long course gives an
overview of the vaccine continuum, covering topics such as vaccine
discovery and development, issues in production and regulation,
methods for safety evaluation, and communications and advocacy.
Intended for policymakers, scientists and public health
professionals from developing countries, the course attracted over
90 participants from 27 countries, including China, India,
Indonesia, Turkey, and Guinea Bissau.
The SIVAC (Supporting Independent Immunization and Vaccine
Advisory Committees) Initiative is a seven-year project carried out by
the Agence de Medecine Preventive (AMP) and IVI with support from
the Bill & Melinda Gates Foundation. It aims to support the
development of sustainable National Immunization Technical
Advisory Groups (NITAGs) in developing countries in Asia and Africa
to enhance the use of evidence-based decision-making processes in the
development of national immunization programs and policies. With
support and technical assistance from IVI, Kyrgyzstan and Kazakhstan
launched their first NITAGs in 2012. They follow Mongolia who
established its first NITAG with IVI’s support in 2010. IVI continued
to provide technical assistance to the Mongolian NITAG - a joint
orientation workshop was held in collaboration with the WHO
Regional Office for the Western Pacific (WPRO) in Ulaanbaatar,
Mongolia.
North Korea Program
The North Korea Program was launched in late 2012 with support
from South Korea’s Ministry of Unification. The program aims to
reduce the burden of diarrheal disease and acute encephalitis
syndrome in children in North Korea by building country capacity
in vaccine introduction. Activities include building the laboratory
infrastructure and training North Korean scientists and public
health personnel in disease surveillance, laboratory diagnostics, and
reporting. This is crucial to generate disease burden data, which
are needed by the government to make evidence-based decisions
on vaccine introduction.
A training workshop on surveillance and laboratory diagnosis was
held for eight North Korean scientists from December 3-8, 2012
in Hanoi, Vietnam in collaboration with Vietnam’s National
Institute of Hygiene and Epidemiology (NIHE). Additional
workshops are planned for 2013.
IVI also provided technical support to Nepal’s National Committee on
Immunization Practice (NCIP) and formed an agreement with the
WHO Nepal country office to support the scientific secretariat of
NCIP. In addition, IVI conducted a joint orientation workshop in
Naypyitaw, Myanmar in collaboration with the WHO Regional
Office for South-East Asia (SEARO) as part of efforts to strengthen
Myanmar’s National Committee of Immunization Practice (NCIP).
IVI scientist and SIVAC regional coordinator, Dr. Batmunkh Nyambat (third from
left, standing) provided support in the establishment of Mongolia’s first National
Immunization Technical Advisory Group.
HIGHLIGHTS IN TRAINING AND CAPACITY-BUILDING
19
FINANCIAL SUMMARY
* Figures are presented in US dollars.
2012
2011
Bill & Melinda Gates Foundation (BMGF)
9,076,267
12,039,652
Government of the Republic of Korea
2,193,155
7,171,608
616,313
413,025
REVENUE
Swedish International Development
Cooperation Agency (Sida)
Corporations / Individuals / Others
Investments (Interest Income)
Total Income
SOURCES OF REVENUE
1%
2%
21%
5,897,021
5,272,607
144,747
524,915
17,927,503
25,421,806
33%
51%
2%
3%
47%
28%
12%
EXPENSES
2012
2011
14,933,906
16,978,834
Laboratory Support
2,024,945
2,315,339
Management & General
4,396,482
4,970,789
Communication & Advocacy
1,071,617
1,117,888
22,426,950
25,382,850
78,360
40,360
(4,421,087)
79,316
2012
2011
6,867,107
14,923,451
26,100,742
21,944,704
1,406,568
838,603
971,327
762,556
35,345,744
38,469,314
Program Services
Total Expense
Foreign Exchange Gain (Loss)
Net Surplus (Deficit)
ASSETS
Cash and Cash Equivalents
Bank Deposits
Other Current Assets
Other assets
Total Assets
Bill & Melinda Gates Foundation (BMGF)
Government of the Republic of Korea
Swedish International Development Cooperation
Agency (Sida)
Corporations / Individuals / Others
Investments (Interest Income)
EXPENSE ALLOCATION
5%
20%
Grant Funds-Deferred support
Other Current Liabilities
2012
2011
25,631,138
23,530,256
1,074,057
1,206,875
Other Liabilities
Net Assets
Total Liabilities and Net Assets
8,640,549
13,732,183
35,345,744
38,469,314
20%
66%
9%
LIABILITIES AND NET ASSETS
4%
67%
9%
Program Services
Laboratory Support
Management & General
Communication & Advocacy
Note: The above financial statement is an excerpt from the IVI’s audited financial statements, which are audited by Samil
PricewaterhouseCoopers. The International Vaccine Institute is an international nonprofit organization. Contributions to the IVI are
tax-exempt under US IRS code 501(c) (3).
20 IVI 2012 ANNUAL REPORT
BOARD OF TRUSTEES
(as of December 31, 2012)
Prof. Ragnar Norrby (Outgoing Chair)
Dr. Suh You-mi (Host Country Representative)
Former Director General
Swedish Institute for Infectious Disease Control
Sweden
Director General
International Cooperation Bureau
Ministry of Education, Science, and Technology
Republic of Korea
Dr. Nguyen Tran Hien
Director
National Institute of Hygiene and Epidemiology
Faculty of Public Health
Hanoi Medical University
Vietnam
Mr. Romulo Garcia (UNDP Representative)
Senior Adviser
Regional Bureau for Asia and the Pacific,
UNDP New York
Dr. Christian Loucq (Ex-officio)
Mr. George Bickerstaff
Managing Director,
M.M. Dillon & Co.,
U.S.A
Director General
International Vaccine Institute
Representatives from State Par ties
Prof. Adel A.F. Mahmoud (Incoming Chair)
Professor
Princeton University
Department of Molecular Biology and the Woodrow
Wilson School of Public and International Affairs
U.S.A.
Dr. Akira Homma
Dr. Juhani Eskola
Prof. Dr. Claire J.P. Boog
Deputy Director General
National Institute for Health and Welfare (THL)
Finland
Scientific Director of Netherlands Vaccine Institute (NVI)
Unit Research and Development & Registration and
Medical Unit
The Netherlands
Dr. Shin Young-soo (WHO Representative)
Regional Director
WHO Western Pacific Regional Office (WPRO)
Philippines
Chairman of Policy and Strategy Council
Institute of Technology for Immunologicals/
Bio-Manguinhos of the Oswaldo Cruz Foundtion (Fiocruz)
Brazil
Dr. Viveka Persson
Uredare / Project Manager
Swedish National Agency for Higher Education
Sweden
Ms. Paik Ji-ah (Host Country Representative)
Director General
International Organizations Bureau
Ministry of Foreign Affairs & Trade
Republic of Korea
FINANCIAL SUMMARY AND BOARD OF TRUSTEES
21
SCIENTIFIC ADVISORY GROUP
(as of December 31, 2012)
Prof. Robert E. Black (Chair)
Dr. G. Balakrish Nair
Professor, International Health
Bloomberg School of Public Health
Johns Hopkins University,
Baltimore, Maryland, U.S.A.
Director
National Institute of Cholera and Enteric Diseases (NICED)
Kolkata, India
Dr. Pearay L. Ogra
Dr. Duane J. Gubler
Professor
Program on Emerging Infectious Diseases
Duke-NUS Graduate Medical School
Singapore
John Sealy Distinguished Chair
Emeritus Professor and Chairman
Department of Pediatrics, State University of
New York at Buffalo Children's Hospital
Buffalo, New York, U.S.A.
Dr. Byoung S. Kwon
Dr. David A. Sack
Endowed Investigator
Division of Cell and Immunobiology
R&D Center for Cancer Therapeutics
National Cancer Center
Goyang, Gyeonggi Province, Republic of Korea
Professor, Department of International Health
Johns Hopkins University Bloomberg School of Public Health
Baltimore, Maryland, U.S.A.
Dr. Claudio F. Lanata
Senior Researcher, Instituto de Investigacion Nutricional
(IIN), Lima, Peru
Science Director, U.S. Navy Medical Research
Unit 6, Callao, Peru
Professor, School of Medicine, Peruvian University of
Applied Sciences, Lima, Peru
Dr. Jacques Louis
Emeritus Professor, Faculty of Medicine,
University of Lausanne, Switzerland
Emeritus Director,
Department of Parasitology and Mycology,
Institut Pasteur, Paris (2003-2008)
Dr. Moon H. Nahm
Professor
Department of Pathology
University of Alabama at Birmingham
Birmingham, Alabama, U.S.A.
22 IVI 2012 ANNUAL REPORT
Dr. Peter Smith
Professor, Department of Epidemiology
and Population Health
London School of Hygiene & Tropical Medicine
London, U.K.
Facilities Commit tee
Dr. Gordon Dougan
Principal Research Scientist
Member of the Board of Management
The Wellcome Trust Sanger Institute
Cambridge, U.K.
Dr. Margaret A. Liu
ProTherImmune, Lafayette, California, U.S.A.
Visiting Professor, Karolinska Institute,
Stockholm, Sweden
Major Donors in 2012
Core funding to IVI is provided by the governments of
the Republic of Korea and Sweden. Public-and
private-sector organizations and individuals also
provide support, both monetary and in-kind, for the
Institute’s research and programs. Prominent
organizations and individuals in Korea provide
support due to efforts of the Korea Support
Committee for IVI (KSC). While there are too many
donors to list here, their generosity is deeply
appreciated. To see the full list of IVI donors, please
refer to the IVI website, http://www.ivi.int.
Amway Korea, Ltd.
Bill & Melinda Gates Foundation
Celltrion, Inc.
Community Chest of Korea
Ewha Womans University
GlaxoSmithKline Biologicals
Government of Republic of Korea
Hyundai-Kia Motors
Inviragen, Inc.
Korea Exchange Bank
Korea Health Industry Development Institute
Korea Racing Authority
Korea Research Council of Fundamental Science and Technology
Korea Research Institute of Bioscience and Biotechnology
Korea Support Committee for the IVI (KSC)
LG Electronics
Merck & Co.
Ministry of Education, Science and Technology (MEST), Republic of Korea
Ministry of Foreign Affairs and Trade (MOFAT), Republic of Korea
Ministry of Unification (MOU), Republic of Korea
National Research Foundation of Korea
PATH Vaccine Solutions
Pfizer
Sanofi Pasteur
Swedish International Development Cooperation Agency (Sida)
World Health Organization (WHO)
Yanghyun Foundation
SCIENTIFIC ADVISORY GROUP AND MAJOR DONORS
23
Major Partners in 2012
•Academy of Medical Sciences, Democratic
•Institut Superieur des Sciences de la
People’s Republic of Korea
•Aga Khan University
•Agence de Medecine Preventive (AMP)
•Ajou University, Republic of Korea
•Applied Strategies, USA
•Armauer Hansen Research Institute (AHRI),
Ethiopia
•AVIR Green Hills Biotechnology AG
•Bandim Health Project
•Bangladesh Institute of Child Health
•Beams Biotechnology Co., Ltd.
•Bernhard Nocht Institute for Tropical
Medicine, Germany
•BioFarma, Indonesia
•Bio-Korea, Republic of Korea
•Caritas Germany
•Celltrion, Republic of Korea
•City District Government of Karachi, Pakistan
•Christian Medical College, India
•Chonbuk National University, Republic of
Korea
•Chungnam National University, Republic of
Korea
•Coalition against Typhoid
•Directorate of Health Services, Department of
Health and Family Welfare, State Government
of Orissa, India
•District Public Health Offices of Lalitpur and
Bakhtapur, Nepal
•Duke University Medical Center
•Ewha Womans University, Republic of Korea
•Emory University
•Ethiopian Health and Nutrition Research
Institute, Ethiopia
•Eubiologics, Republic of Korea
•Expanded Program on Immunization of Sindh
Province, Pakistan
•Fred Hutchinson Cancer Research Center
•GAVI Alliance
•Green Tree Foundation, Republic of Korea
•Hanyang University, Republic of Korea
•icddr,b, Bangladesh
•Indian Council of Medical Research, India
•Instituto Butantan, Brazil
•Institut Pasteur Korea
•Institut Pasteur Senegal
Population (ISSP), Burkina Faso
•Johns Hopkins University - International
Vaccine Access Center (IVAC)
•Kangwon National University, Republic of
Korea
•Kenya Medical Research Institute, Kenya
•Kilimanjaro Christian Medical Centre,
Tanzania
•Konkuk University, Republic of Korea
•Korea National Institute of Health (KNIH)
•Korea Research Institute of Bioscience and
Biotechnology (KRIBB)
•Kumasi Centre for Collaborative Research in
Tropical Medicine, Ghana
•Mahidol University
•Merck & Co.
•Metrosalud ESE / Unidad Hospitalaria
communa Santa Cruz, Medellin, Colombia
•Ministries of Health (Ethiopia, Kazakhstan,
Kyrgyzstan, Mongolia, Sudan)
•Ministries of Public Health (Brazil, Colombia,
Thailand)
•Ministry of Health of Sindh Province, Pakistan
•Ministry of Health and Population, Nepal
•Ministry of Tourism and Civil Aviation, Nepal
•MITRA Samaj, Nepal
•National Center for Communicable Diseases,
Ulaanbaatar, Mongolia
•National Institute for Communicable Diseases
(NICD), South Africa
•National Institute of Cholera & Enteric
Diseases (NICED), India
•National Institutes of Health (NIH), USA
•National Institute of Hygiene and Epidemiology
(NIHE), Vietnam
•Nihon University, Japan
•Oromia Regional Health Bureau, Ethiopia
•Oxford Economic Forecasting
•Patan Hospital, Nepal
•Pan American Health Organization (PAHO)
•PATH, USA
•Pohang University of Science and Technology
(POSTECH), Republic of Korea
•Programa de Estudio y Control de
Enfermedades Tropicales (PECET),
Universidad de Antioquia, Medellin, Colombia
24 IVI 2012 ANNUAL REPORT
•Regional Medical Research Centre,
Bhubaneswar, Orissa, India
•Sabin Vaccine Institute, USA
•Scientific Research Center for
Epidemiological Expertise and Monitoring,
Almaty, Kazakhstan
•Secretaria de Salud, Medellin, Colombia
•Sejong University, Republic of Korea
•Seoul National University, Republic of Korea
•Shantha Biotechnics, India
•SK Chemicals, Republic of Korea
•Stanford University
•Transgovernment Enterprise against
Pandemic Influenza of Korea (TEPIK)
•Trust for Vaccines and Immunization (TVI),
Pakistan
•UNICEF Nepal
•United States Centers for Disease Control
and Prevention (CDC)
•University of Alabama at Birmingham
•University of Antananarivo, Madagascar
•University of Florida
•University of Gezira, Sudan
•University of Gothenburg, Sweden
•University of Melbourne, Australia
•University of Ouagadougou, Burkina Faso
•University of Vermont
•University of Virginia
•University of Wisconsin
•VaBiotech, Vietnam
•Vaccine Technologies, Inc. (VTI)
•Walter Reed Army Institute of Research
(WRAIR)
•Washington University
•Wellcome Trust Sanger Institute, UK
•WHO Initiative for Vaccine Research (IVR)
•WHO Programme for Immunization
Preventable Diseases (IPD), Nepal
•WHO Regional Office for Europe (EURO)
•WHO Regional Office for South-East Asia
(SEARO)
•WHO Regional Office for the Western Pacifi
(WPRO)
•World Health Organization (WHO)
•Yonsei University, Republic of Korea
KOREA SUPPORT COMMITTEE FOR THE IVI (KSC)
Established in 1998, the KSC is a nonprofit organization that mobilizes support in the Republic of Korea for IVI.
The Committee consists of prominent leaders from government, industry, and academia in Korea.
For more information, please visit: http://www.ivi.int/ksc.
HONORARY PRESIDENT
Dr. Chae Young-bog
Prof. Lee Ho-wang
Madam Kim Yoon-ok
Chairman, Gyeong Gi Bio-Center/
Former Minister of Science & Technology
Former President, the National Academy of
Sciences, Republic of Korea
The First Lady of the Republic of Korea
Dr. Chung Won-shik
Prof. Lee Sang-sup
PRESIDENT
Former Prime Minister
Prof. Cho Dong-sung
Dr. Han Seung-soo
Professor Emeritus, Seoul National University
College of Pharmacy / Advisor, Pacificpharma
Co.
Professor, Seoul National University College of
Business Administration
Former Prime Minister
Mr. Lee Se-ung
Dr. Hong Seok hyun
Chairman, Shin Il Co. / Chairman, Seoul Arts
Center / Former President, Korea National
Red Cross
CHAIR OF THE BOARD
Chairman, JoongAng Ilbo
Prof. Park Sang-dai
Mr. Kang Choong-hyun
President, The Korean Federation Science and
Technology Societies / Professor Emeritus,
Seoul National University / Member, the
National Academy of Sciences, Republic of
Korea
President, Samjin Globalnet Co., Ltd.
Prof. Park Soo-gil
Mr. Kang Shin-ho
Chairman, Dong-A Socio Group
Chair Professor, Korea University / Former
Permanent Representative of the Republic of
Korea to the UN
Mr. Kim Jai-son
Dr. Rhee Shang-hi
Publisher, The Samtohsa /
Founding President of KSC /
Former Speaker of General Assembly
Chairman, Greenlife Intellectual Network,
Former President, Korea Patent Attorneys
Association / Former Minister of Science &
Technology
VICE PRESIDENT
Mr. Seo Jung-jin
CEO & Chairman, Celltrion, Inc.
Dr. Kim Kee-hyong
EXECUTIVE DIRECTOR
Prof. Son Bong-ho
Prof. Seong Rho-hyun
President, Korea Ceramics Culture Promotion
Society / Former Minister of Science &
Technology
Dean for Research Affairs, & Professor, Seoul
National University College of Natural Sciences
Prof. Kim Nak-doo
EXECUTIVE ADVISOR
Professor Emeritus, Seoul National University
College of Pharmacy
Prof. Cho Wan-kyoo
Prof. Kim Sang-joo
Former President, Bioindustry Association of
Korea/Former President, Seoul National
University / Former Minister of Education
Former President, the National Academy of
Sciences, Republic of Korea
Dr. Yoon Hong-geun
Prof. Kim Si-joong
Prof. Yu Jae-cheon
Chairman, The Science-Technology Forum /
Former Minister of Science & Technology
President, Sangji University
LEGAL ADVISOR
Mr. Choi Sang-yup
Chairman, Korea Community Sharing
Campaign, Professor Emeritus, Seoul
National University
Prof. Yoo Chong-ha
President, Korea National Red Cross /
Former Minister of Foreign Affairs & Trade
Chairman & CEO, GENESIS BBQ Group
Mr. Won Dae-yunn
Prof. Kwon E. Hyock
Chairman, Korea Fashion Association
BOARD OF TRUSTEES
ADVISOR
Professor Emeritus & Former President, Seoul
National University / Former Minister of
Education / Public Health / Environment
Mr. Chae Hee-byung
Dr. Lee Gil-ya
President, Dongjin Chemical Co., Ltd.
President, KyungWon University
Lawyer, Former Minister of Justice /
Vice Prosecutor-General
Mr. Auh Jin
President, Ahn Gook Pharm.
MAJOR PARTNERS AND KOREA SUPPORT COMMITTEE FOR THE IVI
25
Mr. Chang In-whan
Mr. Kim Sun-ki
Prof. Song Jin-won
President & CEO, KTB Asset Management
President, Bio-Medical Science Co., Ltd
Professor, Korea University College of
Medicine
Mr. Chi Chang-hoon
Mr. Kim Young-je
President & CEO, Korean Air
President & CEO, Sky 72 Golf Club
Dr. Choi Davis
Mr. Lee Doung-young
President, Korea Vaccine Co., Ltd.
CEO, Marketing Production, Seoul Dairy
Cooperative
Mr. Shin Hyun-il
Chairman, Bomoon Corporation
Mr. Chun Hong-jae
CEO, Chun Loss Prevention Co., Ltd.
Chair Professor, Kyungwon University
College of BioNano Technology
Mr. Lee Jae-hoo
Senior Partner, Kim & Chang
Prof. Yim Jeong-bin
Mr. Lee In-jung
Professor, Seoul National University College
of Natural Sciences
Dr. Chung Chan-bok
President & CEO, Bioland
Dr. Yang Kyu Hwan
President & CEO, Taein Co., Ltd.
Prof. Chung Kil-saeng
President, The Korean Academy of Science
Technology; Emeritus & Former President,
Konkuk University
Mr. Chung Pal-do
Chairman, Seoul Weightlifting Federation /
Chairman, Korealand Co.
Mr. Yoo Myung-hwan
Mr. Lee In-serk
Chairman, Global Yoo Myung Co., Ltd.
CEO, SK Chemical Life Science Biz
Dr.Yoon Eun-key
Prof. Lee, Yong-soon
President, Central Officials Training Institute
Chairman, Bethesda Life Foundation /
Professor Emeritus, Seoul National University
Dr. Yoon Kang-jun
President, St. Peter’s Hospital
Dr. Limb Thok-kyu
Prof. Huh Kap-bum
Chairman, Magazine "Diplomacy"
Professor Emeritus & Former Dean, Yonsei
University College of Medicine
Prof. Paek Do-myung
Mr. Jeffrey D. Johns
Professor, Seoul National University Graduate
School of Public Health
Chairman, Partners for the Future Foundation
Mr. Kang Shin-jang, President, Ceragem Co.,
Ltd.
CEO, Liftec Co., Ltd.
Mr. Kim Yong-won
Partner, Samil PriceWaterhouseCoopers
Professor, Yonsei University College of
Medicine
Prof. Hong Seung-hwan
Prof. Park Jung-hee
Professor, Seoul National University College of
Natural Sciences
Professor, Seoul National University
Ms. Kim Eun-sun
Chairman, Boryung Pharm.
Prof. Park Man-ki
Mr. Kim Kyong-ho
Professor Emeritus, Seoul National University
College of Pharmacy
Chairman, Hankyong Instrument & ENG Co.,
Ltd
Mr. Park Nam-seo
CEO, Sanha Engineering & Construction Co.
Mr. Kim Young-kee
Executive Vice President /
CSR Team Leader, LG
Mr. Kim Peter Pum-soo
Chairman, DALA Holdings Co., Ltd.
26 IVI 2012 ANNUAL REPORT
AUDITORS
Prof. Park Kyung A
Mr. Kim Duck-sang
CEO, Sartorius Korea Biotech Co., Ltd.
Mr. You Kyung-nam
Prof. Park Sang-chul
Executive Vice President, Well Aging
Research Center, Samsung Advanced
Institute of Technology
SIGNATORIES TO IVI’S ESTABLISHMENT AGREEMENT